# EU-1-14-952_public-assessment-report_20150313_20150313_sevelamer-carbonate-zentiva-epar-public-assessment-report.pdf

EUROPEAN MEDICINES AGENCY
SCIENCE
MEDICINES
HEALTH
20 November 2014
EMA/CHMP/473530/2014
Committee for Medicinal Products for Human Use (CHMP)
Assessment report
Sevelamer carbonate Zentiva
International non-proprietary name: Sevelamer carbonate
Procedure No. EMEA/H/C/003971
Note
Assessment report as adopted by the CHMP with all information of a commercially confidential nature
deleted.
30 Churchill Place . Canary Wharf . London E14 5EU . United Kingdom
Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact
An agency of the European Union
European Medicines Agency, 2015. Reproduction is authorised provided the source is acknowledged.
Administrative information
Name of the medicinal product:
Sevelamer carbonate Zentiva
Applicant:
Genzyme Europe BV
Gooimeer 10
1411 DD Naarden
The Netherlands
Active substance:
sevelamer carbonate
International Nonproprietary Name:
Sevelamer carbonate
Pharmaco-therapeutic group
(ATC Code):
Sevelamer
(V03AE02)
Therapeutic indication(s):
Sevelamer carbonate Zentiva is indicated for
the control of hyperphosphataemia in adult
patients receiving haemodialysis or peritoneal
dialysis.
Pharmaceutical forms:
Film-coated tablet; Powder for oral suspension
Strengths:
2.4 g and 800 mg
Route of administration:
Oral use
Sevelamer carbonate Zentiva is also indicated
for the control of hyperphosphataemia in adult
patients with chronic kidney disease not on
dialysis with serum phosphorus â‰¥ 1.78
mmol/L.
Sevelamer carbonate Zentiva should be used
within the context of a multiple therapeutic
approach, which could include calcium
supplement, 1,25-dihydroxy Vitamin D3 or one
of its analogues to control the development of
renal bone disease.
Assessment report
EMA/CHMP/473530/2014
Page 2/15
